SCHEMBL4977670

SCHEMBL4977670

Cc1nc2c(O)c(CC[C@@H](O)c3ccccc3)c(C(=O)O)cn2c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 2/20 0.36
KDM4E B2RXH2 3/20 0.35
HSD17B10 Q99714 3/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
GLA P06280 1/20 0.32
RIPK1 Q13546 1/20 0.32
PRKDC P78527 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451120 0.90 PRKDC (0.34) P2RX3ALDH1A1LMNATP53MAPT
SCHEMBL5569978 0.90 LMNA (0.38) KDM4EALDH1A1HPGDLMNATP53
SCHEMBL5569980 0.90 LMNA (0.38) KDM4EALDH1A1HPGDLMNATP53
SCHEMBL4977432 0.90 PRKDC (0.34) P2RX3ALDH1A1LMNATP53MAPT
SCHEMBL5566372 0.90 PRKDC (0.34) P2RX3ALDH1A1LMNATP53MAPT
SCHEMBL5558310 0.89 MAPT (0.39) KDM4EHSD17B10ALDH1A1LMNATP53
SCHEMBL5566461 0.87 KMT2A (0.39) KDM4EHSD17B10ALDH1A1HPGDLMNA
SCHEMBL5566458 0.87 KMT2A (0.39) KDM4EHSD17B10ALDH1A1HPGDLMNA
SCHEMBL5329018 0.87 KMT2A (0.37) KDM4EHSD17B10ALDH1A1HPGDLMNA
SCHEMBL5329027 0.87 KMT2A (0.37) KDM4EHSD17B10ALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326784-B2 Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives ALTANA PHARMA AG (DE) 2008-02-05 US disclosed
US-20070117786-A1 Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives ALTANA PHARMA AG (DE) 2007-05-24 US disclosed
EP-1697358-A1 INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC DIHYDROPYRANO -IMIDAZO -PYRIDINES DERIVATIVES Altana Pharma AG (DE) 2006-09-06 EP disclosed
WO-2005058894-A1 INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC DIHYDROPYRANO -IMIDAZO -PYRIDINES DERIVATIVES ALTANA PHARMA AG (DE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117786-A1 Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives CYP1A1, CYP3A4, CYP19A1 P2RX3 882/4885KDM4E 2425/4885HSD17B10 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.